Suppr超能文献

[复发性乳腺癌的治疗]

[Therapy for recurrent breast cancer].

作者信息

Terasawa T, Koyama H, Wada T, Nishizawa I, Shiba E, Kajita A

出版信息

Gan To Kagaku Ryoho. 1985 Mar;12(3 Pt 1):428-38.

PMID:3890757
Abstract

A multimodal treatment strategy for recurrent breast cancer is described. Occasionally, there are a few patients who have no other detectable distant metastases at the time of locoregional recurrence or of appearance of solitary lung metastasis. In such cases, curative results may be obtained with surgical treatment. In cases too extensive for surgical resection, irradiation is the treatment choice for local control. Radiotherapy is also helpful for painful bone lesions. The important basis for the multimodal approach to recurrent breast cancer is a well-balanced combination of local therapy with surgery or irradiation and systemic polychemoendocrine therapy or polychemotherapy followed by maintenance therapy, to improve the quality of life and survival of patients. Concerning the combined chemoendocrine therapy, many investigators have reported an improved effect with simultaneous or sequential use, but not all of these studies have confirmed the advantage of combination therapy over endocrine- or chemo-therapy alone, either in response rate or survival time. Further prospective randomized studies correlating ER status are needed to evaluate this approach. Immunotherapy used as a maintenance therapy may prolong the duration of remission and survival time.

摘要

本文描述了一种复发性乳腺癌的多模式治疗策略。偶尔会有一些患者在局部区域复发或出现孤立性肺转移时没有其他可检测到的远处转移。在这种情况下,手术治疗可能会获得治愈效果。对于无法进行手术切除的广泛病例,放疗是局部控制的治疗选择。放疗对疼痛性骨病变也有帮助。复发性乳腺癌多模式治疗方法的重要基础是将局部治疗与手术或放疗以及全身多化学内分泌治疗或多化疗后维持治疗进行良好平衡的结合,以提高患者的生活质量和生存率。关于联合化学内分泌治疗,许多研究者报告同时或序贯使用可提高疗效,但并非所有这些研究都证实联合治疗在缓解率或生存时间方面优于单纯内分泌治疗或化疗。需要进一步进行与雌激素受体(ER)状态相关的前瞻性随机研究来评估这种方法。作为维持治疗的免疫疗法可能会延长缓解期和生存时间。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验